Articles

Helping Patients Prepare for the Setbacks in Their Multiple Myeloma Journey
Relapsing during therapy is devastating for patients with cancer. Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, share their best practices for how to interact with patients who will have many questions about what it means for them and what therapy options are next. Read More ›

Next-generation sequencing for targetable mutations in lung cancer is as accurate as single-gene testing with minimal increase in testing cost. Read More ›

A recent review article examined the limited benefit associated with immune checkpoint inhibitor use in patients with non–small-cell lung cancer with poor performance status. Read More ›

Released study results indicate that an interval of ≤50 days from diagnosis to treatment significantly improves outcomes in patients with early-stage lung cancer. Read More ›

Smoking cessation ≥3 weeks prior to lung cancer surgery significantly decreases postoperative complications. Read More ›

Talking to Patients About Setting Expectations for Their Multiple Myeloma Therapy
Setting expectations for patients with cancer can help them prepare for the high and low points in their treatment journey. Join Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, as they talk about the importance of setting expectations early for patients with multiple myeloma. Read More ›

Helping Multiple Myeloma Patients Stay on Therapy with a Team Approach
Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, discuss how they use a team approach to help patients remain on their multiple myeloma therapy and remain on therapy longer. Read More ›

Discussing the Importance of Staying on Therapy for Multiple Myeloma Patients
New treatments for multiple myeloma have brought hope to many patients and their families. However, some patients do not remain adherent to their therapy. Join our experts, Charise Gleason, MSN, NP-C, AOCNP, and Nikki Barkett, RN, BSN, OCN, as they discuss how they help patients understand the importance of remaining on their therapy. Read More ›

First-Line OPDIVO® (nivolumab) in Combination with Chemotherapy in Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Cancer, and Esophageal Adenocarcinoma

In 2022, the COVID-19 pandemic continues to impact the practice of medicine and the dissemination of treatment advances presented in scientific forums. Read More ›

Page 44 of 376


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: